Classification for Staging and Managing Patients with Biopolymer-induced Human Adjuvant Disease

Jaime Eduardo Pachón Suárez, MD*
Marcela C. Salazar, MD†
Victor Z. Rizo, MD‡

Background: Biopolymer-induced human adjuvant disease (BHAD) is a chronic clinical condition that requires surgical intervention, regardless of the presence of symptoms, to minimize the risk of functional, aesthetic, and systemic sequelae and the development of conditions simulating autoimmune disease. We propose a classification for BHAD on the basis of the course of the disease, which will make it possible to assess the damage and difficulty in patients, leading to a more appropriate therapeutic approach.

Methods: A protocol study was implemented. A casuistry of patients with a diagnosis of autoimmune/inflammatory syndrome induced by adjuvants was taken into account according to the Shoenfeld criteria. Qualitative variables were analyzed through frequencies and percentages, and quantitative variables were analyzed with measures of central tendency and dispersion. The diagnostic validity of the signs and symptoms was analyzed using some paraclinical tests.

Results: A total of 190 patients diagnosed with autoimmune/inflammatory syndrome induced by adjuvants with biopolymers in the buttocks and who underwent a surgical procedure by the open, masked technique between January 2017 and December 2020 were selected. Considering each sign and symptom, the location of the biopolymers in different planes, and pathophysiology of the clinical course of the disease, a classification was proposed that takes into account diagnostic imaging findings, local clinical signs, systemic symptoms, systemic clinical signs, and autoimmune markers.

Conclusion: Some signs associated with biomarkers with sensitivity and specificity values can influence the pretest decision to request paraclinicals, improving the diagnostic probability and cost effectiveness in these patients. (Plast Reconstr Surg Glob Open 2022;10:e4137; doi: 10.1097/GOX.0000000000004137; Published online 24 February 2022.)

INTRODUCTION

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) is a broad and general classification that is used to categorize four major syndromes caused due to an immune response to adjuvants—autoimmune macrophagic myofasciitis, silicosis, post-vaccination syndrome, and Gulf War illness. Although this classification has been extrapolated and used for patients with biopolymers, it does not cover specific aspects of biopolymer-induced human adjuvant disease (BHAD).

BHAD is a chronic clinical condition that requires surgical intervention as treatment in 100% of the affected population, regardless of whether they are symptomatic or asymptomatic, to minimize the risk of local and systemic sequelae and the risk of developing conditions that simulate the clinical course of disease of autoimmune etiology. Through the study of the clinical and immunological nature of the disease, ASIA has certain criteria for its diagnosis, but this does not enable staging of the degree of severity that guides the treatment required for the patient. Consequently, it is necessary to create a classification for BHAD on the basis of the nature of the disease that will make it possible to assess the damage and difficulty in the patients, leading to a more appropriate therapeutic approach. The objective of this study is to establish a scale to assess the severity of BHAD based on the natural history of the disease.

Disclosure: The authors do not have financial interest to declare in relation to the content of this article.
This study was carried out from the observational clinical follow-up of patients with BHAD since 2017. Different stages of the disease were noted that helped in surgical practice, enabling an understanding of the sequence of appearance of signs and symptoms, positivity of immunological markers, and the natural course of the disease, taking into account the findings and consistency with the pathophysiology with which a disease staging scale shall be proposed (Tables 1–3). This is due to the fact that a gold standard has not yet been established that makes it possible to compare findings; however, the purpose of the present study was to explore the research field in relation to BHAD.\(^3\)

**METHODS**

The study took into account a casuistry of patients diagnosed with ASIA according to the Shoenfeld criteria who underwent a surgical procedure for biopolymer removal in a plastic surgery clinic in Bogotá, Colombia from 2017 to 2020. These data were used to establish a case definition of BHAD, which was also based on the pathophysiology of the disease. The patients included had complete clinical history data, including data on pre-surgical assessment of plastic surgery and aesthetics and laboratory parameters. Patients with uncontrolled diabetes, arterial hypertension, thyroid disease, active infection, rheumatologic history, and who underwent a surgical procedure by the open, masked technique between January 2017 and December 2020 was conducted, taking into account diagnostic imaging findings, local clinical signs, systemic symptoms, systemic clinical signs, and autoimmune markers. Some signs associated with biomarkers with sensitivity and specificity values can influence the pretest decision to request paraclinicals, improving the diagnostic probability and cost effectiveness in these patients.

**Meaning:** The Pachón classification can be a useful tool for the diagnosis and treatment of BHAD.

**Findings:** A transversal study in a total of 190 patients diagnosed with ASIA with biopolymers in the buttocks and who underwent a surgical procedure by the open, masked technique between January 2017 and December 2020 was conducted, taking into account diagnostic imaging findings, local clinical signs, systemic symptoms, systemic clinical signs, and autoimmune markers. Some signs associated with biomarkers with sensitivity and specificity values can influence the pretest decision to request paraclinicals, improving the diagnostic probability and cost effectiveness in these patients.

**Question:** To propose a classification for biopolymer-induced human adjuvant disease (BHAD).

**Takeaways**

**Table 1. Frequency of Local Signs in Biopolymer-induced Human Adjuvant Disease (BHAD)**

| Local Clinical Signs                  | Quantity | Percentage |
|---------------------------------------|----------|------------|
| Satellite adenopathies                | 190      | 100.0      |
| Erythema                              | 178      | 93.7       |
| Telangiectasias                       | 177      | 93.2       |
| Cutaneous venous dilatations          | 165      | 86.8       |
| Eczema                                | 162      | 85.3       |
| Pachydermosis                         | 155      | 81.6       |
| Morphea                               | 108      | 56.8       |
| Necrosis                              | 5        | 2.6        |
| Epidermolysis                         | 4        | 2.1        |

**Table 2. Frequency of Symptoms in Biopolymer-induced Human Adjuvant Disease (BHAD)**

| Systemic Symptoms                | Quantity | Percentage |
|----------------------------------|----------|------------|
| Mialgies                         | 175      | 92.1       |
| Arthralgias                      | 148      | 77.9       |
| Asthenia                         | 148      | 77.9       |
| Adynamia                         | 148      | 77.9       |
| Headache                         | 74       | 37.4       |
| Abdominal distension             | 76       | 40.0       |
| Hair loss                        | 49       | 25.3       |
| Fever                            | 21       | 11.1       |
| Photophobia                      | 54       | 28.4       |
| Hyperacusis                      | 51       | 26.8       |
| Dry mouth                        | 21       | 11.1       |
| Memory loss                      | 15       | 7.9        |
| Neuropathic pain                 | 105      | 55.3       |
| Sympathetic-reflex dystrophy     | 1        | 0.5        |
| Causalgia                        | 1        | 0.5        |

**Table 3. Frequency of Systemic Clinical Signs in Biopolymer-induced Human Adjuvant Disease (BHAD)**

| Systemic Clinical Signs            | Quantity | Percentage |
|------------------------------------|----------|------------|
| Urticarialiform lesions            | 16       | 8.4        |
| Petechiae                          | 5        | 2.6        |
| Vascular nodules                   | 27       | 14.2       |
| Porcelain scleras                  | 23       | 12.1       |
| Raynaud’s phenomenon without       | 22       | 11.6       |
| rheumatologic history              |          |            |
| Jaundice                           | 9        | 4.7        |
| Skin rashes                        | 5        | 2.6        |
| Terry’s nails                      | 2        | 1.1        |
positive for antinuclear antibodies, lactate dehydrogenase, and lupus anticoagulant. The results are presented in tables and graphs, supported by images of the different skin stages (Figs. 1–5). Some systemic manifestations are also supported in Figures 6 and 7.

A case definition was created based on patients with a history of bearing biopolymers between 6 and 14 years. Patients presenting one or more of the following symptoms: myalgia, arthralgia, asthenia, adynamia, and predominantly sensitive neurological symptoms; positive for any of the following: ANAs, complement proteins C3 and C4, LDH, lupus anticoagulant, or rheumatoid factor; and showing improvement with removal of the material were selected for the study.

### RESULTS

The study sample was composed of 190 patients diagnosed with ASIA with biopolymers in the buttocks and who underwent a surgical procedure by Dr. Jaime Pachón’s open MASK technique between January 2017 and December 2020. In total, 98.4% of patients were women, with a mean age of 41 ± 10.3 (SD) years, and were of various nationalities with the majority being Colombian (120 patients) (63, 16%).

Taking into account the frequencies of the appearance of each of the signs and symptoms, location of the biopolymers in different planes, and pathophysiology of the clinical behavior of the disease, the Pachón classification proposes taking five parameters into consideration: (1) diagnostic imaging findings (MRI), (2) local clinical signs, (3) systemic symptoms, (4) systemic clinical signs, and (5) autoimmune markers (Table 5). This assessment makes it possible to generate a score that categorizes the biopolymer carrier patient with a stage of the disease (mild, moderate, or severe), which in turn allows us to establish an individualized treatment plan (Tables 6, 7).

### Table 4. Frequency of Autoimmune Markers in Biopolymer-induced Human Adjuvant Disease (BHAD)

| Autoimmune Markers                          | Quantity | Percentage |
|---------------------------------------------|----------|------------|
| Negative                                    | 76       | 40         |
| Antinuclear antibodies                      | 114      | 60.0       |
| Lupus anticoagulant                         | 27       | 14.2       |
| Serum complement C3-C4                      | 8        | 4.2        |
| anti SLC-70 antibodies                       | 5        | 2.6        |
| Rheumatoid factor                           | 4        | 2.1        |
| lactate dehydrogenase                       | 38       | 20.0       |
| HLA – B27 (+)                                | 5        | 2.6        |
| Antithyroid peroxidase antibodies           | 3        | 1.6        |
| Glycosylated hemoglobin                     | 3        | 1.6        |
| Carcinoembryonic antigen                    | 2        | 1.1        |
| Alkaline phosphatase beta fraction          | 1        | 0.5        |

Fig. 1. No signs of skin damage.

Fig. 2. Eczema.
Table 8 shows that the sensitivities and specificities of the signs and symptoms are low; however, the PPVs and NPVs of certain signs and symptoms can help in making decisions when thinking about the need to request a diagnostic test. We have reported cases with a history of dry eye, porcelain sclera, memory loss, and necrosis, which had NPV greater than 80%. Moreover, eczema, erythema at the site of the biopolymer, and telangiectasia had PPVs that were also considered good (Table 8).

When the signs and symptoms were evaluated in the sensitivity analysis for the estimation of LDH positivity,9,11 it was shown that adynamia, neurological symptoms, pachydermostosis, nodules, and headache can show sensitivities greater than 80%. Petechiae was the only clinical sign with 100% sensitivity.15,16 In the same way, PPVs were good in patients with eczema and pachydermostosis; finally, memory loss, dry mouth, presence of nodules, and necrosis were favorable, ruling out the disease in their absence due to NPV greater than 80% (Table 9).

In contrast, for lupus anticoagulant, the signs and symptoms showed high values in specificity; however, the signs with higher PPVs were telangiectasias and myalgias, and those with higher NPVs were dry eye, porcelain sclera, necrosis, and dry mouth (Table 10).

**DISCUSSION**

BHAD needs to be considered a public health problem that affects the quality of life and functionality of patients, causing an impact not only on the individual, but also on their family, work environment, and economic productivity. This creates the need to establish worldwide governmental strategies that include prohibition of the administration of biopolymer in the human body through the regulatory entities for substances and drugs in each country, taking into account the alerts issued by the Food and Drug Administration in which emphasis is placed on the danger these products pose.17 Surgical management for the removal of these materials should be safely implemented in both symptomatic and asymptomatic patients, so as to reduce morbidity as well as functional and aesthetic sequelae.18–20

The previous classifications proposed by Shoenfeld and Alijotas18–20 raised the possibility of associating symptoms and paraclinical studies with rheumatological conditions. However, there is a need to create a specific and directed classification of these nonbiocompatible products in the population with biopolymers, which trigger signs and symptoms in the affected population with positive paraclinical studies for immunological conditions.

This study proposes a classification that takes into account severity levels based on the natural course of the disease, evaluated in a cohort of patients from a plastic surgery clinic in Colombia from 2017 to 2020 to stage the damage caused by these materials and the
corresponding treatment. Consequently, three color-coded levels were created; there was no green level because it was assumed that the patient has a material that is not biocompatible with the body. There is a cellular or humoral autoimmune response established from the moment of administration of biopolymer that may be asymptomatic, and it was assumed that all cases of BHAD were mild to severe.

The mild stage of the Pachón classification suggests surgical management without clinical rheumatological intervention; however, a patient who presents some positive immunological paraclinical results and continues to have them post-surgery will require evaluation and follow-up by a rheumatologist. The moderate stage will not only require surgical management with the open technique but also pre- and postoperative rheumatological management with immunomodulatory therapies to mitigate symptoms associated with positive immunological markers. The severe stage will be limited to the management of complications, removal of biopolymer wherever possible, and reconstruction with local or microsurgical flaps as required.

There is no evidence in the literature that patients with ASIA should undergo a multidisciplinary approach for their recovery; however, this study aims at proposing the need for patients with BHAD to have an assessment and follow-up with pain medicine and palliative care, rheumatology, physical rehabilitation therapy, and psychiatry, as

| Nuclear Magnetic Resonance                              | Quantity | Percentage |
|----------------------------------------------------------|----------|------------|
| Biopolymers with local or systemic migration             | 146      | 76.8       |
| Biopolymers with muscle fascia infiltration             | 32       | 16.8       |
| Biopolymers located in the gluteal region               | 13       | 6.8        |
management not only consists of removing the material, but also rehabilitation and accompaniment to overcome the functional and mental sequelae, thereby establishing the need to create health groups or institutions that are experts in biopolymer removal with a multidisciplinary approach. In addition, all patients should have rheumatology follow-up to monitor autoimmune markers such as ANAs, complement C3 and C4 proteins, and lupus anticoagulant.3

According to Pachón et al, BHAD mimics autoimmune diseases with a prevalence of 5.3%, as documented in a plastic surgery clinic in Colombia.3 This study shows the importance of taking complete clinical history, since it is documented that there are some local and systemic signs and symptoms that can be evaluated for the diagnosis of BHAD, which will help in guiding the pretest need to request some paraclinicals with an autoimmune profile such as antinuclear antibodies, LDH, and lupus anticoagulant.7

The decision to request paraclinicals for postoperative follow-up to define whether it is a true autoimmune disease or a simulation will depend on the experience of the physician and the evidence collected. Moreover, this decision will impact the treatment and cost effectiveness.

The general ASIA classifications available for the diagnosis of the disease do not integrate diagnostic images. This study includes MRI findings because they are a presurgical diagnostic aid to evaluate not only the type of material that is expected to be found at the time of surgery, since most patients do not know what it is, but also makes it possible to evaluate the damage at the muscular level and the infiltration of organs or systems, which is directly related to the severity. From this visual assessment, the surgeon can make a plan that enables the maximum removal of the product.

| Table 7. Staging of Severity |
|-----------------------------|
| **Disease Stage** | **Score** | **Treatment** |
| Mild | ≤4 points | Biopolymer removal with open surgical technique + evaluation by psychiatry and physical rehabilitation |
| Moderate | 5–14 points | Biopolymer removal with open surgical technique + evaluation by rheumatology, psychiatry, and physical rehabilitation therapy |
| Severe | ≥15 points | Biopolymer removal with open surgical technique + reconstruction + reconstruction using local flaps or microsurgery + assessment with pain medicine and palliative care, evaluation by physical rehabilitation therapy, rheumatology, and psychiatry |

| Table 6. Scoring and Staging of Severity |
|-----------------------------|
| **Clinical and Paraclinical Diagnostic Criteria** | **Mild (1 Point)** | **Moderate (2 Point)** | **Severe (3 Point)** |
| Simple nuclear magnetic resonance with short tau inversion recovery technique or computed tomography with 3D reconstruction that shows the material | Located in the gluteal region | Material with muscle fascia infiltration | Local or systemic migration |
| Local clinical signs | Satellite lymphadenopathy, erythema, telangiectasia | Varicose cutaneous dilation | Morphea, epidermolysis, necrosis |
| Systemic symptoms | Myalgias | Biopolymer eczema, pachydermottosis |
| Asthenia | Memory loss photophobia |
| Adynamia | Dry mouth |
| Fever | Hyperacusis |
| Headache | |
| Abdominal distention | |
| Urticarial lesion, petechiae, hair loss | Vascular nodules, porcelain sclera |
| Systemic clinical signs | Raynaud’s phenomenon with no known rheumatologic history, skin rashes, jaundice, Terry’s nails |
| Autoimmune markers | Lupus anticoagulant |
| Negative | Hypercomplementemia c3-c4, Rheumatoid factor, SLC-70 |
| Antinuclear antibodies | antibodies for scleroderma |
| | Carcinoembryonic antigen |
| | Alkaline phosphatase beta fraction |

| Table 8. Sensitivity Analysis of Signs and Symptoms versus Antinuclear Antibody |
|-----------------------------|
| **Clinical Features** | **Sensitivity** | **Specificity** | **PPV** | **NPV** |
| Adynamia | 57.43% | 30.95% | 74.56% | 17.11% |
| Asthenia | 57.43% | 30.95% | 74.56% | 17.11% |
| Myalgias | 57.43% | 30.95% | 74.56% | 17.11% |
| Dry eye | 55% | 39.41% | 10% | 88.16% |
| Eczema | 59.26% | 35.71% | 84.21% | 13.16% |
| Erythema | 61.24% | 58.33% | 95.61% | 9% |
| Porcelain sclerae | 65.22% | 40.72% | 13.16% | 89.47% |
| Fever | 52.38% | 39.05% | 10% | 86.84% |
| Hair loss | 64.58% | 41.55% | 27.19% | 77.63% |
| Memory loss | 60% | 40% | 8% | 92.11% |
| Morphea | 58.72% | 38.27% | 56.14% | 40.79% |
| Necrosis | 40% | 39.46% | 2% | 96.05% |
| Neurological symptoms | 55.24% | 34.52% | 51.33% | 38.16% |
| Pachydermottosis | 58.06% | 31.43% | 78.95% | 14.47% |
| Abdominal distention | 52% | 34.78% | 34.21% | 52.63% |
| Photophobia | 53.70% | 37.78% | 25.66% | 67.11% |
| Telangiectasias | 61.02% | 53.85% | 94.74% | 9% |
Table 9. Sensitivity Analysis of Signs and Symptoms versus Dehydrogenase Lactate (LDH)

| Clinical Features       | Dehydrogenase Lactate |
|-------------------------|------------------------|
|                          | Sensitivity | Specificity | PPV | NPV |
| Adynamia                 | 84.46%      | 16.67%      | 78.13% | 23.33% |
| Asthenia                 | 21.23%      | 85%         | 83.78% | 22.82% |
| Arthralgias              | 84.46%      | 16.67%      | 78.13% | 23.33% |
| Dry eye                  | 80%         | 15.29%      | 10%   | 86.67% |
| Eczema                   | 85.8%       | 25%         | 86.88% | 23.33% |
| Erythema                 | 85.39%      | 33.33%      | 95%   | 13.33% |
| Porcelain sclerae       | 13.04%      | 78.79%      | 7.89%  | 86.67% |
| Fever                    | 71.43%      | 14.2%       | 9.37%  | 80%   |
| Hair loss                | 87.5%       | 16.9%       | 26.25% | 80%   |
| Memory loss              | 66.67%      | 14.29%      | 6.25%  | 83.33% |
| Morphea                  | 22.64%      | 81.25%      | 61.54% | 44.22% |
| Necrosis                 | 60%         | 15.4%       | 1.87%  | 93.33% |
| Neurological symptoms    | 83.81%      | 15.48%      | 55.35% | 43.33% |
| Pachydermostosis         | 85.16%      | 20%         | 82.5%  | 23.33% |
| Abdominal distension     | 10.81%      | 84.96%      | 6.25%  | 83.33% |
| Photophobia              | 81.48%      | 14.81%      | 27.67% | 66.67% |
| Cutaneous venous dilatations | 84.85%  | 20%         | 87.5%  | 16.67% |
| Dry mouth                | 80.95%      | 15.38%      | 10.63% | 86.67% |
| Hypercalcemia            | 84.51%      | 15.97%      | 37.5%  | 63.33% |
| Hyperacidity             | 81.48%      | 14.81%      | 27.67% | 66.67% |
| Vascular nodules         | 85.19%      | 15.95%      | 14.37% | 86.67% |
| Petechiae                | 100%        | 16.22%      | 3.12%  | 100%  |

Table 10. Sensitivity Analysis of Signs and Symptoms versus Lupus Anticoagulant

| Clinical Features       | Lupus Anticoagulant |
|-------------------------|----------------------|
|                          | Sensitivity | Specificity | PPV | NPV |
| Adynamia                 | 85.71%      | 16.89%      | 22.64% | 80.65% |
| Asthenia                 | 16.89%      | 85.71%      | 80.65% | 22.64% |
| Arthralgias              | 16.22%      | 83.35%      | 77.42% | 22.01% |
| Dry eye                  | 15%         | 83.53%      | 10%   | 89.31% |
| Eczema                   | 12.96%      | 64.29%      | 67.74% | 11.32% |
| Erythema                 | 89.29%      | 5.66%       | 14.29% | 73%   |
| Porcelain sclerae       | 8.33%       | 86.96%      | 8.69%  | 86.42% |
| Fever                    | 9.09%       | 88.27%      | 9.52%  | 87.73% |
| Hair loss                | 12.50%      | 82.39%      | 19.35% | 73.38% |
| Memory loss              | 3.70%       | 91.98%      | 7.14%  | 85.14% |
| Morphea                  | 9%          | 74.07%      | 29.26% | 56.84% |
| Necrosis                 | 20%         | 83.78%      | 3%    | 97.48% |
| Neurological symptoms    | 12.38%      | 87.57%      | 41.94% | 41.77% |
| Pachydermostosis         | 12.90%      | 68.57%      | 64.52% | 15.09% |
| Abdominal distension     | 32%         | 59.26%      | 10.81% | 84.96% |
| Photophobia              | 16.67%      | 83.70%      | 29.03% | 71.52% |
| Telangiectasias          | 16.38%      | 84.62%      | 93.55% | 7%    |
| Dry mouth                | 14.29%      | 85.43%      | 10%   | 88.68% |
| Headache                 | 11.27%      | 80.67%      | 25.81% | 60.38% |
| Myalgia                  | 16%         | 80%         | 90.92% | 8%    |

In addition to the aforementioned findings, we found that in some patients, there was an elevation in alkaline phosphatase level, related to the migration of the product to bone or periosteal structures, alteration of glycosylated hemoglobin related to alteration of metabolic pathways, or presence of positive thyroid peroxidase antibodies. These aspects have been previously described in other medical conditions of metabolic or autoimmune origin. Lactate dehydrogenase is a factor of severity in the behavior of the biopolymer and makes it possible to define an early surgical approach, mitigating the symptoms and chronic inflammatory behavior of the disease.

As a limitation of the study, it is considered that a control group was missing to compare and generate the association between immunological markers and human adjuvant disease caused by biopolymer that would allow us to give more power to the diagnostic decision measures. Prospective, analytical studies with epidemiological association are recommended.

**CONCLUSIONS**

Many of the signs and symptoms described by patients and identified in clinical practice are associated with specific biomarkers involved in immunological processes and can influence the pretest decision to request paraclinicals, improving the diagnostic probability and cost effectiveness. The complex clinical presentation of the biopolymer as well as its pathophysiology makes it a difficult condition to diagnose and treat. This proposal seeks to suggest a tool for the classification of patients created from the natural course of the disease observed and documented in the author's clinical practice. Further research on BHAD should be continued to strengthen the standards of diagnosis, classification, and treatment in such patients and to unify concepts for the common benefit.

**REFERENCES**

1. Watad A, Quaresma M, Brown S, et al. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome) – an update. Lupus. 2017;26:675–681.
2. Alijotas-Reig J. Human adjuvant-related syndrome or autoimmune/inflammatory syndrome induced by adjuvants. Where have we come from? Where are we going? A proposal for new diagnostic criteria. Lupus. 2015;24:1012–1018.
3. Pachón SJE, Salazar MC, Fores AM, et al. Clinical and immunological characteristics of patients with biopolymers and autoimmune inflammatory syndrome induced by adjuvants. Plast Reconstr Surg Glob Open. 2021;9:e5796.
4. Pavlov-Dolijanovic S, Vujasinovic Stupar N. Women with silicone breast implants and autoimmune inflammatory syndrome induced by adjuvants: description of three patients and a critical review of the literature. Rheumatol Int. 2017;37:1405–1411.
5. Watad A, Quaresma M, Bragazi NL, et al. The autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome): descriptive analysis of 300 patients from the international ASIA syndrome registry. Clin Rheumatol. 2018;37:483–493.
6. Carvantes-Cortes MI, Roldan-Valadez E, Zwojewski-Martinez RD, et al. Breast prosthesis syndrome: pathophysiology and management algorithm. Aesthetic Plast Surg. 2020;44:1423–1437.
7. Araujo Santiago E, De Paula IB. Autoimmune/inflammatory syndrome induced by adjuvants (Asia syndrome) associated with silicone breast implant rupture. Arch Breast Cancer. 2021;8:156–161.
8. Choi JH, Yu KP, Yoon YS, et al. Relationship between HbA1c and complex regional pain syndrome in stroke patients with type 2 diabetes mellitus. Ann Rehabil Med. 2016;40:779–785.
9. Ban EJ, Kim D, Kim JK, et al. Lactate Dehydrogenase A as a potential new biomarker for thyroid cancer. Endocrinoi Metab (Seoul). 2021;36:96–105.
10. Ayano M, Arinobu Y, Tsukamoto H, et al. Shoulder ultrasound and serum lactate dehydrogenase predict inadequate response...
to glucocorticoid treatment in patients with polymyalgia rheumatica. *Rheumatol Int.* 2020;40:1101–1109.
11. Babu VS, Sharma S, Manas RK, et al. Study of serum creatine kinase and lactate dehydrogenase levels and their correlation in high-voltage electric contact burns. *Eur J Plast Surg.* 2021;44:103–110.
12. Colaris MJL, van der Hulst RR, Tervaert JWC. Vitamin D deficiency as a risk factor for the development of autoantibodies in patients with ASIA and silicone breast implants: a cohort study and review of the literature. *Clin Rheumatol.* 2017;36:981–993.
13. Al-Mendalawi M. Prevalence of thyroid dysfunction in patients with systemic lupus erythematosus: a descriptive cross-sectional study. *Indian J Rheumatol.* 2020;15:252.
14. Ahmad J, Blumen H, Tagoe CE. Association of antithyroid peroxidase antibody with fibromyalgia in rheumatoid arthritis. *Rheumatol Int.* 2015;35:1415–1421.
15. Ushiyama S, Shimojima Y, Ueno KI, et al. Clinical characteristics of patients with myalgia as the initial manifestation of small and medium-sized vasculitis: a retrospective study. *Rheumatol Int.* 2020;40:1667–1674.
16. Hudacko R, Anand K, Gordon R, et al. Hepatic silicone granulomas secondary to ruptured breast implants: a report of two cases. *Case Reports Hepatol.* 2019;2019:7348168.
17. FDA warnings against use of injectable silicone for body contouring and enhancement: FDA safety communication [Internet]. 2017. Available at https://www.fda.gov/news-events/press-announcements/fda-warns-about-illegal-use-injectable-silicone-body-contouring-and-associated-health-risks. Accessed November 19, 2021.
18. Arango MT, Perricone C, Kivity S, et al. HLA-DRB1 the notorious gene in the mosaic of autoimmunity. *Immunol Res.* 2017;65:82–98.
19. Scanzi F, Andreoli L, Martinelli M, et al. Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures. *Immunol Res.* 2017;65:150–156.
20. Alijotas-Reig J, Esteve-Valverde E, Gil-Alberas N, et al. Autoimmune/inflammatory syndrome induced by adjuvants–ASIA-related to biomaterials: analysis of 45 cases and comprehensive review of the literature. *Immunol Res.* 2018;66:120–140.